Overview

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Participants With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Status:
Not yet recruiting
Trial end date:
2024-12-29
Target enrollment:
Participant gender:
Summary
The study aims to compare and assess the dose response of 3 selected doses of AMG 133 compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with diabetes mellitus (Cohort B).
Phase:
Phase 2
Details
Lead Sponsor:
Amgen